Calidi Biotherapeutics Appoints New CMO, Director

Ticker: CLDWW · Form: 8-K · Filed: Apr 23, 2025 · CIK: 1855485

Calidi Biotherapeutics, Inc. 8-K Filing Summary
FieldDetail
CompanyCalidi Biotherapeutics, Inc. (CLDWW)
Form Type8-K
Filed DateApr 23, 2025
Risk Levelmedium
Sentimentneutral

Sentiment: neutral

Topics: management-change, board-appointment, material-agreement

Related Tickers: CLDI

TL;DR

Calidi Biotherapeutics brings in new leadership with a new CMO and board member, plus a material agreement.

AI Summary

Calidi Biotherapeutics, Inc. announced on April 17, 2025, the appointment of Dr. Sarah E. Michaels as Chief Medical Officer and the election of Mr. David M. E. Smith to its Board of Directors. The company also entered into a material definitive agreement related to its ongoing clinical trials. These changes are effective immediately.

Why It Matters

The appointment of a new Chief Medical Officer and a board member suggests strategic shifts and potential growth initiatives for Calidi Biotherapeutics.

Risk Assessment

Risk Level: medium — Changes in key executive and board positions, along with material agreements, can indicate significant strategic shifts or challenges for the company.

Key Players & Entities

  • Calidi Biotherapeutics, Inc. (company) — Registrant
  • Dr. Sarah E. Michaels (person) — Appointed Chief Medical Officer
  • Mr. David M. E. Smith (person) — Elected to Board of Directors
  • April 17, 2025 (date) — Date of earliest event reported

FAQ

Who has been appointed as the new Chief Medical Officer?

Dr. Sarah E. Michaels has been appointed as the new Chief Medical Officer.

Who has been elected to the Board of Directors?

Mr. David M. E. Smith has been elected to the Board of Directors.

What is the date of the earliest event reported in this 8-K filing?

The date of the earliest event reported is April 17, 2025.

What type of agreement did Calidi Biotherapeutics enter into?

Calidi Biotherapeutics entered into a material definitive agreement.

What was Calidi Biotherapeutics' former company name?

Calidi Biotherapeutics' former company name was First Light Acquisition Group, Inc.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on April 23, 2025 by Dr. Sarah E. Michaels regarding Calidi Biotherapeutics, Inc. (CLDWW).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.